McKesson (MCK)
Market Price (9/18/2026): $877.05 | Market Cap: $104.1 BilSector: Health Care | Industry: Health Care Distributors
McKesson (MCK)
Market Price (9/18/2026): $877.05Market Cap: $104.1 BilSector: Health CareIndustry: Health Care Distributors
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldFCF Yield is 5.9% Stock buyback supportStock Buyback 3Y Total is 13 Bil Attractive cash flow generationCFO LTM is 6.9 Bil, FCF LTM is 6.1 Bil Low stock price volatilityVol 12M is 31% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, Digital Health & Telemedicine, Precision Medicine, and Cloud Computing. Show more. | Key risksMCK key risks include [1] significant ongoing liabilities from litigation over its role in opioid distribution and [2] legal challenges related to allegations of misleading investors about generic drug pricing. |
| Attractive yieldFCF Yield is 5.9% |
| Stock buyback supportStock Buyback 3Y Total is 13 Bil |
| Attractive cash flow generationCFO LTM is 6.9 Bil, FCF LTM is 6.1 Bil |
| Low stock price volatilityVol 12M is 31% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, Digital Health & Telemedicine, Precision Medicine, and Cloud Computing. Show more. |
| Key risksMCK key risks include [1] significant ongoing liabilities from litigation over its role in opioid distribution and [2] legal challenges related to allegations of misleading investors about generic drug pricing. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 9/1/2026
McKesson (MCK) stock has gained about 20% since 5/31/2026 because of the following key factors:
1. Exceptional Fiscal Q1 2027 Financial Performance and Upgraded Outlook. McKesson reported robust results for its fiscal Q1 2027, which ended on June 30, 2026. The company announced an adjusted Earnings Per Share (EPS) of $9.93, surpassing analyst estimates of approximately $9.64, representing a 20% increase year-over-year. Revenues also climbed 8% to $105.4 billion, exceeding forecasts. This strong performance was largely driven by significant operating profit gains of 19% in the North American Pharmaceutical segment and an impressive 41% in the Oncology & Multispecialty segments, fueled by increased prescription volumes and specialty drug distribution. Following these strong results, McKesson raised its full-year fiscal 2027 adjusted EPS guidance to a range of $44.20-$45.00, up from the previous range of $43.80-$44.60.
2. Strategic Acquisition to Enhance Oncology and Biopharma Services. On August 25, 2026, McKesson announced a definitive agreement to acquire Precision Medicine Group for approximately $2.25 billion. This acquisition is set to significantly expand McKesson's capabilities in clinical research, drug development, and biopharma commercialization services. Precision Medicine Group will be integrated into McKesson's high-growth Oncology & Multispecialty segment, further strengthening the company's position in this critical area of healthcare.
Show more
McKesson (MCK) stock has gained about 20% since 5/31/2026 because of the following key factors:
1. Exceptional Fiscal Q1 2027 Financial Performance and Upgraded Outlook. McKesson reported robust results for its fiscal Q1 2027, which ended on June 30, 2026. The company announced an adjusted Earnings Per Share (EPS) of $9.93, surpassing analyst estimates of approximately $9.64, representing a 20% increase year-over-year. Revenues also climbed 8% to $105.4 billion, exceeding forecasts. This strong performance was largely driven by significant operating profit gains of 19% in the North American Pharmaceutical segment and an impressive 41% in the Oncology & Multispecialty segments, fueled by increased prescription volumes and specialty drug distribution. Following these strong results, McKesson raised its full-year fiscal 2027 adjusted EPS guidance to a range of $44.20-$45.00, up from the previous range of $43.80-$44.60.
2. Strategic Acquisition to Enhance Oncology and Biopharma Services. On August 25, 2026, McKesson announced a definitive agreement to acquire Precision Medicine Group for approximately $2.25 billion. This acquisition is set to significantly expand McKesson's capabilities in clinical research, drug development, and biopharma commercialization services. Precision Medicine Group will be integrated into McKesson's high-growth Oncology & Multispecialty segment, further strengthening the company's position in this critical area of healthcare.
Show more
Updated on 9/1/2026
McKesson (MCK) stock has gained about 20% since 5/31/2026 because of the following key factors:
1. Exceptional Fiscal Q1 2027 Financial Performance and Upgraded Outlook. McKesson reported robust results for its fiscal Q1 2027, which ended on June 30, 2026. The company announced an adjusted Earnings Per Share (EPS) of $9.93, surpassing analyst estimates of approximately $9.64, representing a 20% increase year-over-year. Revenues also climbed 8% to $105.4 billion, exceeding forecasts. This strong performance was largely driven by significant operating profit gains of 19% in the North American Pharmaceutical segment and an impressive 41% in the Oncology & Multispecialty segments, fueled by increased prescription volumes and specialty drug distribution. Following these strong results, McKesson raised its full-year fiscal 2027 adjusted EPS guidance to a range of $44.20-$45.00, up from the previous range of $43.80-$44.60.
2. Strategic Acquisition to Enhance Oncology and Biopharma Services. On August 25, 2026, McKesson announced a definitive agreement to acquire Precision Medicine Group for approximately $2.25 billion. This acquisition is set to significantly expand McKesson's capabilities in clinical research, drug development, and biopharma commercialization services. Precision Medicine Group will be integrated into McKesson's high-growth Oncology & Multispecialty segment, further strengthening the company's position in this critical area of healthcare.
3. Increased Shareholder Returns through Dividend Growth and Share Repurchases. McKesson demonstrated a strong commitment to shareholder returns during this period. On July 21, 2026, the Board of Directors approved a 15% increase in the quarterly dividend, raising it from $0.82 to $0.94 per share, marking the tenth consecutive year of dividend increases. Additionally, in fiscal Q1 2027, McKesson completed $2.5 billion in share repurchases, including $2.25 billion under an accelerated share repurchase program, and outlined plans for approximately $5 billion in share repurchases for the full fiscal year 2027.
Show less
McKesson (MCK) stock has gained about 20% since 5/31/2026 because of the following key factors:
1. Exceptional Fiscal Q1 2027 Financial Performance and Upgraded Outlook. McKesson reported robust results for its fiscal Q1 2027, which ended on June 30, 2026. The company announced an adjusted Earnings Per Share (EPS) of $9.93, surpassing analyst estimates of approximately $9.64, representing a 20% increase year-over-year. Revenues also climbed 8% to $105.4 billion, exceeding forecasts. This strong performance was largely driven by significant operating profit gains of 19% in the North American Pharmaceutical segment and an impressive 41% in the Oncology & Multispecialty segments, fueled by increased prescription volumes and specialty drug distribution. Following these strong results, McKesson raised its full-year fiscal 2027 adjusted EPS guidance to a range of $44.20-$45.00, up from the previous range of $43.80-$44.60.
2. Strategic Acquisition to Enhance Oncology and Biopharma Services. On August 25, 2026, McKesson announced a definitive agreement to acquire Precision Medicine Group for approximately $2.25 billion. This acquisition is set to significantly expand McKesson's capabilities in clinical research, drug development, and biopharma commercialization services. Precision Medicine Group will be integrated into McKesson's high-growth Oncology & Multispecialty segment, further strengthening the company's position in this critical area of healthcare.
3. Increased Shareholder Returns through Dividend Growth and Share Repurchases. McKesson demonstrated a strong commitment to shareholder returns during this period. On July 21, 2026, the Board of Directors approved a 15% increase in the quarterly dividend, raising it from $0.82 to $0.94 per share, marking the tenth consecutive year of dividend increases. Additionally, in fiscal Q1 2027, McKesson completed $2.5 billion in share repurchases, including $2.25 billion under an accelerated share repurchase program, and outlined plans for approximately $5 billion in share repurchases for the full fiscal year 2027.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 18.7% change in MCK stock from 5/31/2026 to 9/17/2026 was primarily driven by a 19.4% change in the company's P/E Multiple.| (LTM values as of) | 5312026 | 9172026 | Change |
|---|---|---|---|
| Stock Price ($) | 740.83 | 879.57 | 18.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 403,430 | 410,983 | 1.9% |
| Net Income Margin (%) | 1.2% | 1.1% | -5.3% |
| P/E Multiple | 19.0 | 22.7 | 19.4% |
| Shares Outstanding (Mil) | 122 | 119 | 3.1% |
| Cumulative Contribution | 18.7% |
Market Drivers
5/31/2026 to 9/17/2026| Return | Correlation | |
|---|---|---|
| MCK | 18.7% | |
| Market (SPY) | 0.8% | -32.7% |
| Sector (XLV) | 12.9% | 49.4% |
Fundamental Drivers
The -10.7% change in MCK stock from 2/28/2026 to 9/17/2026 was primarily driven by a -18.6% change in the company's P/E Multiple.| (LTM values as of) | 2282026 | 9172026 | Change |
|---|---|---|---|
| Stock Price ($) | 984.41 | 879.57 | -10.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 397,958 | 410,983 | 3.3% |
| Net Income Margin (%) | 1.1% | 1.1% | 2.5% |
| P/E Multiple | 27.9 | 22.7 | -18.6% |
| Shares Outstanding (Mil) | 123 | 119 | 3.8% |
| Cumulative Contribution | -10.7% |
Market Drivers
2/28/2026 to 9/17/2026| Return | Correlation | |
|---|---|---|
| MCK | -10.7% | |
| Market (SPY) | 11.5% | -17.9% |
| Sector (XLV) | 5.8% | 44.6% |
Fundamental Drivers
The 28.8% change in MCK stock from 8/31/2025 to 9/17/2026 was primarily driven by a 33.3% change in the company's Net Income Margin (%).| (LTM values as of) | 8312025 | 9172026 | Change |
|---|---|---|---|
| Stock Price ($) | 683.13 | 879.57 | 28.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 377,595 | 410,983 | 8.8% |
| Net Income Margin (%) | 0.8% | 1.1% | 33.3% |
| P/E Multiple | 27.0 | 22.7 | -15.7% |
| Shares Outstanding (Mil) | 125 | 119 | 5.2% |
| Cumulative Contribution | 28.8% |
Market Drivers
8/31/2025 to 9/17/2026| Return | Correlation | |
|---|---|---|
| MCK | 28.8% | |
| Market (SPY) | 19.2% | -10.7% |
| Sector (XLV) | 24.4% | 29.1% |
Fundamental Drivers
The 115.9% change in MCK stock from 8/31/2023 to 9/17/2026 was primarily driven by a 54.4% change in the company's P/E Multiple.| (LTM values as of) | 8312023 | 9172026 | Change |
|---|---|---|---|
| Stock Price ($) | 407.44 | 879.57 | 115.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 284,040 | 410,983 | 44.7% |
| Net Income Margin (%) | 1.3% | 1.1% | -15.4% |
| P/E Multiple | 14.7 | 22.7 | 54.4% |
| Shares Outstanding (Mil) | 136 | 119 | 14.2% |
| Cumulative Contribution | 115.9% |
Market Drivers
8/31/2023 to 9/17/2026| Return | Correlation | |
|---|---|---|
| MCK | 115.9% | |
| Market (SPY) | 75.3% | 0.5% |
| Sector (XLV) | 32.7% | 28.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MCK Return | 45% | 52% | 24% | 24% | 45% | 8% | 428% |
| Peers Return | 27% | 19% | 10% | -5% | 55% | 10% | 172% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| MCK Win Rate | 67% | 67% | 75% | 75% | 75% | 67% | |
| Peers Win Rate | 54% | 56% | 52% | 46% | 65% | 58% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| MCK Max Drawdown | -9% | -11% | -13% | -24% | -11% | -27% | |
| Peers Max Drawdown | -16% | -22% | -21% | -24% | -16% | -22% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: COR, CAH, CVS, HSIC. See MCK Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/17/2026 (YTD)
How Low Can It Go
| Event | MCK | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -30.9% | -33.7% |
| % Gain to Breakeven | 44.7% | 50.9% |
| Time to Breakeven | 227 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -16.8% | -19.2% |
| % Gain to Breakeven | 20.2% | 23.8% |
| Time to Breakeven | 42 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -25.5% | -3.7% |
| % Gain to Breakeven | 34.3% | 3.9% |
| Time to Breakeven | 216 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -30.4% | -12.2% |
| % Gain to Breakeven | 43.7% | 13.9% |
| Time to Breakeven | 1994 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -22.6% | -6.8% |
| % Gain to Breakeven | 29.2% | 7.3% |
| Time to Breakeven | 151 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -15.5% | -17.9% |
| % Gain to Breakeven | 18.4% | 21.8% |
| Time to Breakeven | 23 days | 123 days |
In The Past
McKesson's stock fell -0.8% during the 2025 US Tariff Shock. Such a loss loss requires a 0.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | MCK | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -30.9% | -33.7% |
| % Gain to Breakeven | 44.7% | 50.9% |
| Time to Breakeven | 227 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -25.5% | -3.7% |
| % Gain to Breakeven | 34.3% | 3.9% |
| Time to Breakeven | 216 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -30.4% | -12.2% |
| % Gain to Breakeven | 43.7% | 13.9% |
| Time to Breakeven | 1994 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -22.6% | -6.8% |
| % Gain to Breakeven | 29.2% | 7.3% |
| Time to Breakeven | 151 days | 15 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -56.9% | -53.4% |
| % Gain to Breakeven | 132.0% | 114.4% |
| Time to Breakeven | 495 days | 1085 days |
In The Past
McKesson's stock fell -0.8% during the 2025 US Tariff Shock. Such a loss loss requires a 0.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About McKesson (MCK)
McKesson Corporation (MCK) is a pivotal global healthcare company primarily engaged in pharmaceutical distribution, medical supply management, and advanced healthcare information technology solutions. Founded in 1833, the company plays a critical role in the healthcare supply chain, ensuring that a vast array of pharmaceutical drugs and medical supplies reach healthcare providers and patients efficiently. Its operations span both the United States and international markets, supporting the complex needs of the healthcare ecosystem.
The company's core services are delivered through several key segments. Its U.S. Pharmaceutical segment is a major distributor of branded, generic, specialty, and over-the-counter drugs, also offering practice management, technology, and business solutions to pharmacies and specialty care practices. Internationally, McKesson provides similar distribution and services to wholesale, institutional, and retail customers across numerous European countries and Canada. Additionally, its Medical-Surgical Solutions segment focuses on distributing essential medical-surgical supplies and logistics services to healthcare providers.
A significant component of McKesson's business involves its Prescription Technology Solutions (RxTS) segment, which provides innovative healthcare information and technology. This includes solutions like CoverMyMeds, designed to help patients access their medications, and RelayHealth, a workflow solution for healthcare professionals. McKesson also offers services to biopharma manufacturers and custom pharmacy automation technology. Its primary customer base encompasses pharmacies, hospitals, community-based oncology and specialty practices, biopharma manufacturers, and various other healthcare providers, highlighting its comprehensive footprint in the healthcare industry.
AI Analysis | Feedback
- The Amazon for the healthcare supply chain.
- The FedEx/UPS for prescription medications and medical supplies.
AI Analysis | Feedback
- Pharmaceutical Distribution: Distributes a wide range of branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare products in the U.S. and internationally.
- Medical-Surgical Supply Distribution: Provides medical-surgical supply distribution, logistics, and other services to healthcare providers.
- Pharmacy & Specialty Practice Solutions: Offers practice management, technology, clinical support, business, financial, operational, and consulting services for pharmacies and community-based specialty practices.
- CoverMyMeds: A solution designed to help patients obtain and manage their medications.
- Rx Technology & Automation: Provides workflow solutions (RelayHealth), services for biopharma manufacturers (RxCrossroads), customized pharmacy automation technology, and multi-client central fill services.
AI Analysis | Feedback
McKesson Corporation (MCK) primarily sells to other companies and organizations within the healthcare industry. The provided company description does not identify specific major customer companies by name or symbol. Instead, McKesson serves a vast and diverse network of businesses across various segments of the healthcare supply chain. Based on the company's operations, its major customer categories include:
- Pharmacies: This encompasses a wide range of pharmacies, including independent retail pharmacies, large chain pharmacies, hospital pharmacies, and specialty pharmacies.
- Healthcare Providers and Institutions: This category includes hospitals, health systems, clinics, community-based oncology practices, other specialty practices, and various long-term care facilities.
- Biopharma Manufacturers: McKesson provides solutions and services to biopharmaceutical manufacturers, particularly through its Prescription Technology Solutions (RxTS) segment.
- Wholesale Customers: Especially within its International segment, McKesson serves other wholesale distributors, in addition to direct institutional and retail customers.
AI Analysis | Feedback
- Pfizer Inc. (PFE)
- Johnson & Johnson (JNJ)
- Merck & Co., Inc. (MRK)
- AbbVie Inc. (ABBV)
- Eli Lilly and Company (LLY)
- Bristol-Myers Squibb Company (BMY)
- Amgen Inc. (AMGN)
- Gilead Sciences, Inc. (GILD)
AI Analysis | Feedback
Brian Tyler, Chief Executive Officer
Brian Tyler became Chief Executive Officer of McKesson Corporation in April 2019, having joined the company in 1997. He has held a diverse range of leadership positions across McKesson, including Chief Operations Officer, Chairman of the Management Board of McKesson Europe, President of North American Pharmaceutical Distribution and Services, President of U.S. Pharmaceutical, Medical-Surgical, and Specialty Health divisions, and Executive Vice President of Corporate Strategy and Business Development, where he oversaw corporate strategy and mergers and acquisitions (M&A). Before his tenure at McKesson, he was a Senior Associate at Integral, Inc., a healthcare consulting firm. Tyler also served on the board of directors of VistaCare until its merger in 2008. He currently serves on the board of directors for Republic Services and the International Federation of Pharmaceutical Wholesalers (IFPW).
Britt Vitalone, Executive Vice President and Chief Financial Officer
Britt Vitalone assumed the role of Executive Vice President and Chief Financial Officer in January 2018, having joined McKesson in 2006. His prior roles at McKesson include Senior Vice President & CFO of McKesson U.S. Pharmaceutical and Specialty Health, Senior Vice President of Corporate Finance and Merger & Acquisition (M&A) Finance, and Senior Vice President & CFO of McKesson Medical-Surgical. Vitalone possesses extensive expertise in mergers and acquisitions and portfolio management. Before joining McKesson, he held various financial leadership positions at GE Capital Corporation, Pembrooke Occupational Health, and CarMax.
Tracy Faber, Executive Vice President & Chief Human Resources Officer
Tracy Faber serves as Executive Vice President & Chief Human Resources Officer for McKesson. Prior to joining McKesson in 2011 as Senior Vice President of Human Resources, she spent 13 years with PepsiCo in executive HR capacities. She also led the HR department at Eaton Corporation and Nabisco. Her contributions at McKesson include building relations capability and leading change management efforts for the company's strategic transformation.
Nancy Flores, Executive Vice President, Chief Information Officer, and Chief Technology Officer
Nancy Flores is McKesson's Executive Vice President, Chief Information Officer, and Chief Technology Officer. In this role, she is responsible for enterprise business technology governance, strategy, risk management, IT security, service delivery, and infrastructure operations. She also oversees the company's overall technology initiatives for healthcare technology products and supports application development processes.
Tom Rodgers, Executive Vice President & Chief Strategy and Business Development Officer
Tom Rodgers was appointed Executive Vice President & Chief Strategy and Business Development Officer in June 2020. He is responsible for McKesson's overall initiatives, strategic plans, acquisitions, and internal programs designed to enhance financial performance, foster innovation, and deliver customer value. His background includes significant experience in both large healthcare and venture capital environments.
AI Analysis | Feedback
The key risks for McKesson (MCK) largely stem from the highly regulated and competitive nature of the healthcare and pharmaceutical distribution industries.
- Regulatory and Legal Risks: McKesson operates within a highly regulated healthcare environment, subjecting it to extensive healthcare, environmental, and privacy regulations. This leads to significant compliance costs and exposure to potential legal actions. The company faces ongoing litigation and regulatory scrutiny, particularly concerning its role in distributing controlled substances like opioids, which could result in substantial financial liabilities and reputational damage. Furthermore, changes in healthcare reform efforts, reimbursement methodologies, and new regulations related to drug pricing transparency and access to care pose continuous threats to its business model and profitability.
- Competitive Pressure and Margin Compression: McKesson operates in a highly competitive industry with significant pressure from peers, which can erode profit margins and affect its ability to negotiate favorable terms with suppliers and customers. The pharmaceutical distribution business is characterized by massive volumes and typically "razor-thin" margins. There has been a trend of decreasing gross profit margins, driven by factors such as generic drug price deflation and the buying power of large retail national accounts. Maintaining market share in this environment requires continuous investment in technology and services, further straining financial resources.
- Operational and Supply Chain Risks: Given McKesson's extensive role in healthcare supply chain management and technology solutions, it faces significant operational risks. These include cybersecurity threats, which could compromise technology systems and lead to data breaches. The company's reliance on third-party service providers also introduces risks related to outsourcing and potential supply chain disruptions. Additionally, issues affecting product efficacy or safety at any point from manufacturing, storing, to distributing, or dispensing could result in recalls, regulatory actions, civil lawsuits, fines, and reputational harm.
AI Analysis | Feedback
The potential for Amazon to leverage its extensive logistics network, technological capabilities, and increasing presence in healthcare (e.g., Amazon Pharmacy, PillPack, RxPass) to expand aggressively into large-scale, B2B pharmaceutical and medical-surgical wholesale distribution, directly competing with McKesson's core distribution segments. This represents an emerging threat by a well-capitalized, technologically advanced company with a history of disrupting established industries through efficiency and direct-to-customer or direct-to-business models, potentially bypassing traditional distribution channels.
AI Analysis | Feedback
McKesson Corporation operates in several large addressable markets across its segments. Here are the estimated market sizes for its main products and services:
U.S. Pharmaceutical Segment
- Pharmaceutical Distribution (branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs): The U.S. pharmaceutical market size was estimated at USD 634.34 billion in 2024 and is projected to reach approximately USD 1,107.4 billion by 2034.
- Pharmaceutical Logistics (part of pharmaceutical distribution): The U.S. pharmaceutical logistics market size was estimated at USD 26.5 billion in 2023 and is projected to grow to USD 45.22 billion by 2030.
- Practice Management, Technology, Clinical Support, and Business Solutions to Community-Based Oncology and other Specialty Practices: The community oncology services market in the U.S. was valued at USD 70.44 billion in 2025 and is expected to increase to USD 161.32 billion by 2032. Another estimate indicates the U.S. community oncology services market is expected to grow to $81.33 billion in 2027.
International Segment
- Pharmaceutical Wholesale and Distribution (Europe and Canada):
- Global Pharmaceutical Wholesale and Distribution: The global pharmaceutical wholesale and distribution market is projected to reach approximately USD 1.5 trillion by 2033.
- Europe Pharmaceutical Market: The Europe pharmaceutical market size was estimated at USD 488.05 billion in 2024 and is projected to reach USD 1,032.76 billion by 2034.
- Europe Pharmaceutical Logistics: The Europe pharmaceutical logistics market size is estimated at USD 90.30 billion in 2025 and is expected to reach USD 109.44 billion by 2030.
- Canada Pharmaceutical Market: The Canada pharmaceutical market size was valued at USD 51.56 billion in 2024 and is projected to grow to USD 95.70 billion by 2033.
Medical-Surgical Solutions Segment
- Medical-Surgical Supply Distribution, Logistics, and other Services: While a specific market size for medical-surgical supply distribution was not distinctly identified, the broader global pharmaceutical wholesale and distribution market, which includes medical supplies distribution (medical devices, surgical supplies, diagnostic equipment), is projected to reach approximately USD 1.5 trillion by 2033.
Prescription Technology Solutions (RxTS) Segment
- Patient Medication Access (CoverMyMeds solution): The U.S. patient access solutions market was estimated at USD 485.11 million in 2024 and is projected to reach USD 1043.57 million by 2035. The global patient access solutions market was valued at USD 1.86 billion in 2023 and is expected to reach USD 3.70 billion by 2032.
- Pharmacy Management Systems (RelayHealth workflow solution): The U.S. pharmacy management system market was valued at US$ 21,017.59 million in 2022 and is expected to reach US$ 53,139.59 million by 2030.
- Biopharma Manufacturer Services (RxCrossroads solution): The global biopharma service market size was valued at approximately USD 22 billion in 2023 and is projected to reach around USD 50 billion by 2032. The U.S. biopharmaceuticals contract manufacturing market size was estimated at USD 5.64 billion in 2025 and is expected to surpass around USD 8.45 billion by 2035. The global pharma contract commercialization market, with North America expected to have the highest share, is valued at USD 42.6 billion in 2024 and is predicted to reach USD 69.7 billion by 2034.
- Pharmacy Automation (McKesson Prescription Automation): The U.S. pharmacy automation devices market size was estimated at USD 2.73 billion in 2023 and is expected to grow to USD 5.01 billion by 2030. The North America pharmacy automation market size was valued at USD 3.49 billion in 2024 and is expected to reach USD 7.43 billion by 2032.
- Central Fill as a Service (Multi-Client Central Fill as a Service): The global central fill pharmacy automation market was valued at USD 0.6 billion in 2024 and is expected to reach USD 1.5 billion by 2034. The North America central fill pharmacy automation market size was over USD 1.04 billion in 2025 and is poised to exceed USD 3.29 billion by 2035.
AI Analysis | Feedback
McKesson Corporation (MCK) is expected to drive future revenue growth over the next 2-3 years through several key strategies:
-
Growth in North American Pharmaceutical Distribution
McKesson anticipates continued robust performance in its North American Pharmaceutical segment. This growth is primarily fueled by increasing prescription volumes, including higher demand across retail national account customers and the expanding distribution of specialty pharmaceutical products, such as GLP-1 medications. -
Expansion of Oncology and Multispecialty Care
The company is strategically investing in and expanding its oncology and multispecialty platforms. This involves growing its U.S. Oncology Network through new practice partnerships, expanding the distribution of oncology and other multispecialty products, and making targeted acquisitions to strengthen its position in these high-growth, higher-margin healthcare areas. -
Advancement of Prescription Technology Solutions (RxTS) and Biopharma Services
McKesson expects significant revenue growth from its Prescription Technology Solutions and Biopharma Services segments. This growth is driven by increased demand for access solutions, including prior authorizations for specialized medications, as well as an enhanced focus on digital transformation, AI investments, and partnerships with biopharmaceutical manufacturers. -
Strategic Acquisitions and Portfolio Optimization
McKesson is actively pursuing strategic acquisitions and optimizing its portfolio to focus on higher-growth, higher-margin opportunities. This includes integrating advanced data analytics and AI capabilities, as exemplified by recent acquisitions, and the planned divestiture of its Medical-Surgical Solutions business to sharpen its strategic focus on pharmaceutical and specialty services.
AI Analysis | Feedback
Share Repurchases
- McKesson's Board of Directors approved a $4.0 billion increase to the share repurchase program in July 2024, raising the total authorization to $9.9 billion.
- The company repurchased $3.146 billion in shares in fiscal year 2025, $3.025 billion in fiscal year 2024, and $3.638 billion in fiscal year 2023.
- For the first three months of fiscal year 2025 (ending June 30, 2024), McKesson returned $527 million to shareholders through common stock repurchases.
Share Issuance
- McKesson has not had significant share issuances; instead, its shares outstanding have been declining. For instance, shares outstanding decreased by 4.47% in 2025, 5.7% in 2024, and 7.72% in 2023.
Outbound Investments
- McKesson acquired an 80% interest in Prism Vision Group for $850 million in February 2025.
- Other recent acquisitions by McKesson include Rx Savings Solutions and OncoHealth in 2022.
Capital Expenditures
- McKesson's capital expenditures averaged $439.4 million annually for the fiscal years ending March 2021 to 2025.
- Capital expenditures reached a five-year peak of $537 million in March 2025.
- The company anticipates capital expenditures will gradually increase to support business growth, with a forecast of remaining below $2.4 billion in 2026, primarily focused on safety, reliability, and select growth projects.
Peer Outperformance in Health Care Distributors
MCK has outperformed 83% of its 6 Health Care Distributors peers over 5Y. Health Care Distributors ranks 1st of 10 industries in Health Care by median 5Y return. That makes it one of the strongest corners of the sector.
Share of Health Care Distributors constituents that MCK has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
83%
of 6 industry peers · 27.6% return
3Y
83%
of 6 industry peers · 108.3% return
5Y
83%
of 6 industry peers · 333.8% return
No Health Care Distributors peer with a comparable growth profile has beaten MCK by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Health Care Distributors is MCK's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors ← | 7 | 7.8% | 77.2% | 101.1% | CAH 380% · MCK 334% · COR 164% |
| Managed Health Care | 8 | 40.9% | -1.4% | 1.5% | OSCR 83% · HQY 48% · ELV 17% |
| Health Care Services | 20 | 25.4% | 42.2% | -1.8% | HIMS 219% · RDNT 172% · DGX 76% |
| Health Care Facilities | 24 | 5.6% | 0.8% | -12.7% | NHC 274% · THC 259% · ENSG 127% |
| Health Care Equipment | 50 | -0.8% | -4.9% | -21.9% | POCI 10800% · UFPT 334% · GKOS 199% |
| Pharmaceuticals | 62 | -5.1% | 12.4% | -39.8% | LQDA 2442% · INDV 1175% · ETON 1012% |
| Health Care Supplies | 12 | 17.1% | -12.2% | -40.3% | LNTH 294% · HAE 53% · MMSI 19% |
| Life Sciences Tools & Services | 109 | 5.4% | -22.1% | -68.8% | SNWV 1586% · MEDP 231% · NTRA 190% |
| Health Care Technology | 21 | -25.5% | -51.1% | -79.7% | SPOK 72% · HSTM 1% · VEEV -13% |
| Biotechnology | 364 | 0.4% | -26.6% | -79.8% | DNTH 1198% · CELZ 1154% · ELVN 1077% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 226.34 |
| Mkt Cap | 59.8 |
| Rev LTM | 332,771 |
| Op Inc LTM | 4,529 |
| FCF LTM | 4,525 |
| FCF 3Y Avg | 3,209 |
| CFO LTM | 5,174 |
| CFO 3Y Avg | 3,778 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.4% |
| Rev Chg 3Y Avg | 7.7% |
| Rev Chg Q | 6.7% |
| QoQ Delta Rev Chg LTM | 1.6% |
| Op Inc Chg LTM | 36.6% |
| Op Inc Chg 3Y Avg | 15.4% |
| Op Mgn LTM | 1.7% |
| Op Mgn 3Y Avg | 1.4% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 2.0% |
| CFO/Rev 3Y Avg | 1.6% |
| FCF/Rev LTM | 1.8% |
| FCF/Rev 3Y Avg | 1.3% |
Segment Financials
Revenue by Segment| $ Mil | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| North American Pharmaceutical | 336,652 | 304,507 | 261,368 | ||
| Oncology & Multispecialty | 48,423 | 36,862 | 30,490 | ||
| Medical-Surgical Solutions | 11,507 | 11,380 | 11,309 | 11,110 | 11,608 |
| Prescription Technology Solutions | 5,805 | 5,216 | 4,769 | 4,387 | 3,864 |
| Other | 1,043 | 1,086 | 1,015 | ||
| Corporate | 0 | ||||
| International | 20,598 | 36,345 | |||
| United States (US) Pharmaceutical | 240,616 | 212,149 | |||
| Total | 403,430 | 359,051 | 308,951 | 276,711 | 263,966 |
| $ Mil | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| North American Pharmaceutical | 3,658 | 2,945 | 2,338 | ||
| Oncology & Multispecialty | 1,149 | 767 | 707 | ||
| Prescription Technology Solutions | 1,044 | 875 | 835 | 566 | 500 |
| Medical-Surgical Solutions | 938 | 779 | 955 | 1,117 | 959 |
| Other | 590 | 54 | 57 | ||
| International | 136 | -968 | |||
| United States (US) Pharmaceutical | 3,206 | 2,879 | |||
| Total | 7,379 | 5,420 | 4,892 | 5,025 | 3,370 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| United States (US) Pharmaceutical | 46,812 | 41,793 | 38,346 | 35,236 | 33,541 |
| International | 6,535 | 6,226 | 13,717 | 14,987 | 14,994 |
| Medical-Surgical Solutions | 6,233 | 5,780 | 5,830 | 5,986 | 5,395 |
| Prescription Technology Solutions | 4,385 | 4,168 | 3,528 | 3,446 | 3,786 |
| Corporate | 3,478 | 4,353 | 1,877 | 5,360 | 3,531 |
| Total | 67,443 | 62,320 | 63,298 | 65,015 | 61,247 |
Price Behavior
Price Behavior
| Market Price | $879.57 | |
| Market Cap ($ Bil) | 104.4 | |
| First Trading Date | 11/15/1994 | |
| Distance from 52W High | -11.5% | |
| 50 Days | 200 Days | |
| DMA Price | $864.34 | $842.42 |
| DMA Trend | indeterminate | up |
| Distance from DMA | 1.8% | 4.4% |
| 3M | 1YR | |
| Volatility | 32.0% | 31.5% |
| Downside Capture | -136.52 | -40.99 |
| Upside Capture | -35.76 | -5.11 |
| Correlation (SPY) | -31.9% | -10.9% |
MCK Betas & Captures as of 8/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.83 | -1.03 | -0.87 | -0.40 | -0.27 | 0.01 |
| Up Beta | -0.60 | -1.74 | -1.24 | -0.56 | -0.36 | 0.04 |
| Down Beta | 3.53 | 0.58 | -0.11 | 0.16 | -0.32 | -0.09 |
| Up Capture | -87% | -44% | -49% | -39% | -1% | 5% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 10 | 21 | 32 | 59 | 133 | 423 |
| Down Capture | -263% | -236% | -194% | -59% | -64% | -28% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 11 | 21 | 32 | 68 | 118 | 328 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MCK | |
|---|---|---|---|---|
| MCK | 27.5% | 31.4% | 0.79 | - |
| Sector ETF (XLV) | 25.0% | 16.1% | 1.19 | 28.4% |
| Equity (SPY) | 16.6% | 12.9% | 0.92 | -11.3% |
| Gold (GLD) | 17.4% | 29.3% | 0.55 | -7.4% |
| Commodities (DBC) | 45.8% | 20.7% | 1.72 | -7.4% |
| Real Estate (VNQ) | 5.7% | 13.5% | 0.16 | 16.1% |
| Bitcoin (BTCUSD) | -34.9% | 43.9% | -0.85 | -23.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MCK | |
|---|---|---|---|---|
| MCK | 34.5% | 24.9% | 1.16 | - |
| Sector ETF (XLV) | 6.3% | 15.2% | 0.23 | 36.4% |
| Equity (SPY) | 12.6% | 17.2% | 0.56 | 14.7% |
| Gold (GLD) | 18.9% | 18.8% | 0.81 | -3.0% |
| Commodities (DBC) | 11.7% | 19.6% | 0.47 | 1.7% |
| Real Estate (VNQ) | 1.0% | 18.8% | -0.05 | 16.0% |
| Bitcoin (BTCUSD) | 10.4% | 52.5% | 0.38 | -1.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MCK | |
|---|---|---|---|---|
| MCK | 17.8% | 29.1% | 0.61 | - |
| Sector ETF (XLV) | 10.6% | 16.7% | 0.51 | 51.7% |
| Equity (SPY) | 15.1% | 18.0% | 0.71 | 37.5% |
| Gold (GLD) | 12.0% | 16.4% | 0.60 | 0.7% |
| Commodities (DBC) | 8.5% | 18.1% | 0.39 | 12.0% |
| Real Estate (VNQ) | 4.4% | 20.7% | 0.17 | 31.8% |
| Bitcoin (BTCUSD) | 62.0% | 66.1% | 1.02 | 4.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 9/8/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/5/2026 | -0.7% | 0.2% | 5.1% |
| 5/7/2026 | -2.5% | -1.0% | 1.7% |
| 2/4/2026 | 16.5% | 16.0% | 11.9% |
| 11/5/2025 | 1.7% | -0.4% | -5.4% |
| 9/18/2025 | -0.3% | 9.9% | 12.0% |
| 5/8/2025 | 0.5% | 2.4% | 2.7% |
| 2/5/2025 | -1.2% | -2.0% | 6.3% |
| 11/6/2024 | 10.6% | 13.7% | 10.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 14 | 17 | 18 |
| # Negative | 10 | 7 | 6 |
| Median Positive | 5.2% | 5.8% | 5.5% |
| Median Negative | -1.8% | -2.0% | -4.7% |
| Max Positive | 16.5% | 17.4% | 19.2% |
| Max Negative | -11.3% | -10.5% | -18.2% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/5/2026 | -0.7% | 0.2% | 5.1% |
| 5/7/2026 | -2.5% | -1.0% | 1.7% |
| 2/4/2026 | 16.5% | 16.0% | 11.9% |
| 11/5/2025 | 1.7% | -0.4% | -5.4% |
| 9/18/2025 | -0.3% | 9.9% | 12.0% |
| 5/8/2025 | 0.5% | 2.4% | 2.7% |
| 2/5/2025 | -1.2% | -2.0% | 6.3% |
| 11/6/2024 | 10.6% | 13.7% | 10.0% |
| 8/7/2024 | -11.3% | -10.5% | -18.2% |
| 5/7/2024 | -0.4% | 1.1% | 7.5% |
| 2/7/2024 | -4.4% | -3.1% | 2.1% |
| 11/1/2023 | -2.6% | 0.2% | 1.1% |
| 8/2/2023 | 5.3% | 3.7% | -0.0% |
| 5/8/2023 | 5.5% | 6.1% | 4.5% |
| 2/1/2023 | -1.2% | -1.2% | -6.7% |
| 11/1/2022 | 2.0% | 2.3% | -0.5% |
| 8/3/2022 | 3.3% | 9.9% | 11.4% |
| 5/5/2022 | 6.0% | 2.2% | 0.9% |
| 2/2/2022 | 3.5% | 7.9% | 9.2% |
| 11/1/2021 | 5.2% | 5.8% | 3.7% |
| 8/4/2021 | -2.8% | -3.9% | 0.9% |
| 5/6/2021 | 6.8% | 5.8% | 5.8% |
| 2/2/2021 | 0.5% | 2.3% | -3.9% |
| 11/3/2020 | 5.2% | 17.4% | 19.2% |
| SUMMARY STATS | |||
| # Positive | 14 | 17 | 18 |
| # Negative | 10 | 7 | 6 |
| Median Positive | 5.2% | 5.8% | 5.5% |
| Median Negative | -1.8% | -2.0% | -4.7% |
| Max Positive | 16.5% | 17.4% | 19.2% |
| Max Negative | -11.3% | -10.5% | -18.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/05/2026 | 10-Q |
| 03/31/2026 | 05/08/2026 | 10-K |
| 12/31/2025 | 02/04/2026 | 10-Q |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-K |
| 12/31/2024 | 02/06/2025 | 10-Q |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-K |
| 12/31/2023 | 02/08/2024 | 10-Q |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/02/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-K |
| 12/31/2022 | 02/02/2023 | 10-Q |
| 09/30/2022 | 11/02/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/05/2026 | 10-Q |
| 03/31/2026 | 05/08/2026 | 10-K |
| 12/31/2025 | 02/04/2026 | 10-Q |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-K |
| 12/31/2024 | 02/06/2025 | 10-Q |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-K |
| 12/31/2023 | 02/08/2024 | 10-Q |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/02/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-K |
| 12/31/2022 | 02/02/2023 | 10-Q |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-K |
| 12/31/2021 | 02/03/2022 | 10-Q |
| 09/30/2021 | 11/02/2021 | 10-Q |
| 06/30/2021 | 08/05/2021 | 10-Q |
| 03/31/2021 | 05/12/2021 | 10-K |
| 12/31/2020 | 02/02/2021 | 10-Q |
| 09/30/2020 | 11/03/2020 | 10-Q |
| 06/30/2020 | 08/03/2020 | 10-Q |
| 03/31/2020 | 05/22/2020 | 10-K |
| 12/31/2019 | 02/04/2020 | 10-Q |
| 09/30/2019 | 10/30/2019 | 10-Q |
Recent Forward Guidance
Updated 8/6/2026Latest: Q1 2027 Earnings Reported 8/5/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Adjusted Earnings per Diluted Share | Reported | 44.2 | 44.6 | 45 | 0.9% | Raised | Guidance: 44.2 for 2027 | |
| 2027 Adjusted Earnings per Diluted Share Growth | Reported | 13.0% | 14.0% | 15.0% | 1.0% | Raised | Guidance: 13.0% for 2027 | |
Prior: Q4 2026 Earnings Reported 5/7/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 North American Pharmaceutical Operating Profit Growth | Reported | 5.0% | 6.5% | 8.0% | ||||
| 2027 Oncology & Multispecialty Operating Profit Growth | Reported | 13.0% | 14.5% | 16.0% | ||||
| 2027 Prescription Technology Solutions Operating Profit Growth | Reported | 10.0% | 11.5% | 13.0% | ||||
| 2027 Adjusted EPS | Reported | 43.8 | 44.2 | 44.6 | 13.3% | Higher New | Actual: 39 for 2026 | |
| 2027 Adjusted EPS Growth | Reported | 12.0% | 13.0% | 14.0% | -5.0% | Lower New | Actual: 18.0% for 2026 | |
| 2027 Long-term Adjusted EPS Growth | Reported | 13.0% | 14.5% | 16.0% | ||||
Q3 2026 Earnings Reported 2/4/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Adjusted Earnings per Diluted Share | Reported | 38.8 | 39 | 39.2 | 1.0% | Raised | Guidance: 38.6 for 2026 | |
| 2026 Adjusted Earnings per Diluted Share Growth | Reported | 17.0% | 18.0% | 19.0% | 1.0% | Raised | Guidance: 17.0% for 2026 | |
Insider Activity
Updated 9/10/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Rutledge, Napoleon B JR | SVP, Controller & CAO | Direct | Sell | 9102026 | 891.45 | 111 | 98,951 | 464,445 | Form |
| 2 | Lerman, Bradley E | Direct | Sell | 8112026 | 892.33 | 301 | Form | |||
| 3 | Tyler, Brian S | Chief Executive Officer | Direct | Sell | 7082026 | 793.56 | 8,463 | 6,715,898 | 4,697,082 | Form |
| 4 | Tyler, Brian S | Chief Executive Officer | Direct | Sell | 6182026 | 775.13 | 8,463 | 6,559,925 | 11,147,920 | Form |
| 5 | Tyler, Brian S | Chief Executive Officer | Direct | Sell | 6112026 | 763.00 | 4,929 | 3,760,827 | 17,430,735 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Rutledge, Napoleon B JR | SVP, Controller & CAO | Direct | Sell | 9102026 | 891.45 | 111 | 98,951 | 464,445 | Form |
| 2 | Lerman, Bradley E | Direct | Sell | 8112026 | 892.33 | 301 | Form | |||
| 3 | Tyler, Brian S | Chief Executive Officer | Direct | Sell | 7082026 | 793.56 | 8,463 | 6,715,898 | 4,697,082 | Form |
| 4 | Tyler, Brian S | Chief Executive Officer | Direct | Sell | 6182026 | 775.13 | 8,463 | 6,559,925 | 11,147,920 | Form |
| 5 | Tyler, Brian S | Chief Executive Officer | Direct | Sell | 6112026 | 763.00 | 4,929 | 3,760,827 | 17,430,735 | Form |
| 6 | Rutledge, Napoleon B JR | SVP, Controller & CAO | Direct | Sell | 6082026 | 764.00 | 133 | 101,612 | 482,848 | Form |
| 7 | Rodgers, Thomas L | EVP, Chief Strategy & BDO | Direct | Sell | 6032026 | 735.27 | 699 | 513,954 | 1,667,592 | Form |
| 8 | Rodgers, Thomas L | EVP, Chief Strategy & BDO | Direct | Sell | 6032026 | 735.50 | 123 | 90,466 | 2,182,228 | Form |
| 9 | Smith, Leann B | EVP & Chief HR Officer | Direct | Sell | 6022026 | 735.50 | 1,810 | 1,331,255 | 3,528,929 | Form |
| 10 | Lau, Michele | EVP and Chief Legal Officer | Direct | Sell | 5272026 | 761.09 | 3,550 | 2,701,870 | 2,471,259 | Form |
| 11 | Rodgers, Thomas L | EVP, Chief Strategy & BDO | Direct | Sell | 5272026 | 761.09 | 2,388 | 1,817,483 | 2,351,768 | Form |
| 12 | Lau, Michele | EVP and Chief Legal Officer | Direct | Sell | 3042026 | 990.00 | 2,725 | 2,697,750 | 3,214,530 | Form |
| 13 | Martinez, Maria | Direct | Sell | 2232026 | 939.87 | 349 | 328,013 | 282,899 | Form | |
| 14 | Smith, Leann B | EVP & Chief HR Officer | Direct | Sell | 2182026 | 945.00 | 190 | 179,550 | 2,824,605 | Form |
| 15 | Lau, Michele | EVP and Chief Legal Officer | Direct | Sell | 2132026 | 933.39 | 303 | 282,817 | 5,574,205 | Form |
| 16 | Rutledge, Napoleon B JR | SVP, Controller & CAO | Direct | Sell | 2092026 | 955.00 | 328 | Form | ||
| 17 | Rodgers, Thomas L | EVP, Chief Strategy & BDO | Direct | Sell | 1062026 | 816.18 | 276 | 225,266 | 1,851,096 | Form |
| 18 | Rutledge, Napoleon B JR | SVP, Controller & CAO | Direct | Sell | 11102025 | 861.63 | 329 | 283,476 | 282,615 | Form |
Investor Activity (13F)
Updated Sep 18, 202613F holdings as of Mar 31, 2026 (Q1 2026)
Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| SurgoCap Partners LP | $301.8 Mil | 10.1% | 14 | TRIM -16.8% | 13F |
| Horiko Capital Management LLC | $38.3 Mil | 8.8% | 20 | Hold | 13F |
| Muhlenkamp & Co Inc | $23.5 Mil | 6.2% | 29 | Hold | 13F |
| Bristol Gate Capital Partners Inc. | $81.4 Mil | 5.2% | 31 | TRIM -6.1% | 13F |
| Firetrail Investments PTY LTD | $14.1 Mil | 4.8% | 28 | TRIM -9.4% | 13F |
| Stanley Capital Management, LLC | $24.9 Mil | 4.2% | 40 | Hold | 13F |
| Raub Brock Capital Management LP | $14.6 Mil | 3.7% | 43 | New | 13F |
| Walter Public Investments Inc. | $15.0 Mil | 3.6% | 48 | ADD +118.2% | 13F |
| Lone Pine Capital LLC | $339.4 Mil | 2.7% | 36 | New | 13F |
| Investment Management Associates Inc /Adv | $9.5 Mil | 2.6% | 27 | Hold | 13F |
| Haverford Financial Services, Inc. | $8.3 Mil | 2.5% | 46 | Hold | 13F |
| Kinsale Capital Group, Inc. | $14.8 Mil | 2.4% | 41 | Hold | 13F |
| Schwerin Boyle Capital Management Inc | $13.8 Mil | 1.8% | 47 | TRIM -32.1% | 13F |
| Act Two Investors LLC | $7.7 Mil | 1.7% | 36 | Hold | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | As Of | Filing |
|---|---|---|---|---|---|---|
| Napean Trading & Investment Co (Singapore) PTE Ltd | $12.2 Mil | 2.4% | 37 | Exited | Dec 31, 2025 | 13F |
| Avidity Partners Management LP | $7.8 Mil | 2.3% | 39 | Exited | Dec 31, 2025 | 13F |
| Schwerin Boyle Capital Management Inc | $13.8 Mil | 1.8% | 47 | TRIM -32.1% | Mar 31, 2026 | 13F |
| SurgoCap Partners LP | $301.8 Mil | 10.1% | 14 | TRIM -16.8% | Mar 31, 2026 | 13F |
| Firetrail Investments PTY LTD | $14.1 Mil | 4.8% | 28 | TRIM -9.4% | Mar 31, 2026 | 13F |
| Bristol Gate Capital Partners Inc. | $81.4 Mil | 5.2% | 31 | TRIM -6.1% | Mar 31, 2026 | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Lone Pine Capital LLC | $339.4 Mil | 2.7% | 36 | New | 13F |
| SurgoCap Partners LP | $301.8 Mil | 10.1% | 14 | TRIM -16.8% | 13F |
| Bristol Gate Capital Partners Inc. | $81.4 Mil | 5.2% | 31 | TRIM -6.1% | 13F |
| Horiko Capital Management LLC | $38.3 Mil | 8.8% | 20 | Hold | 13F |
| Stanley Capital Management, LLC | $24.9 Mil | 4.2% | 40 | Hold | 13F |
| Muhlenkamp & Co Inc | $23.5 Mil | 6.2% | 29 | Hold | 13F |
| Walter Public Investments Inc. | $15.0 Mil | 3.6% | 48 | ADD +118.2% | 13F |
| Kinsale Capital Group, Inc. | $14.8 Mil | 2.4% | 41 | Hold | 13F |
| Raub Brock Capital Management LP | $14.6 Mil | 3.7% | 43 | New | 13F |
| Firetrail Investments PTY LTD | $14.1 Mil | 4.8% | 28 | TRIM -9.4% | 13F |
| Schwerin Boyle Capital Management Inc | $13.8 Mil | 1.8% | 47 | TRIM -32.1% | 13F |
| Investment Management Associates Inc /Adv | $9.5 Mil | 2.6% | 27 | Hold | 13F |
| Haverford Financial Services, Inc. | $8.3 Mil | 2.5% | 46 | Hold | 13F |
| Act Two Investors LLC | $7.7 Mil | 1.7% | 36 | Hold | 13F |
McKesson — Investor Video Playlist
Products & Services
McKesson | Powering Care Locally
Products & Services
McKesson | Always Advancing Cancer Research & Care
Products & Services
McKesson Experience Center: The Future of Healthcare
Products & Services
Always Advancing: New Therapy Access
Products & Services
McKesson | Always Advancing Cell and Gene Therapy
Products & Services
McKesson | Always Advancing Precision and Personalized Medicine
Products & Services
McKesson | Always Advancing The True Meaning of Partnership
Investor / Analyst
McKesson (MCK|$89.1B) - 2025 Q4 & Full Year Earnings Analysis
Investor / Analyst
[Beat Expectations] McKesson - 2025 Q2 Earnings Analysis
Products & Services
McKesson | Biomedical Solutions
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 9/17/2026